gestational%20diabetes%20mellitus
GESTATIONAL DIABETES MELLITUS
Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).

Introduction

Gestational Diabetes Mellitus (GDM)
  • Any degree of glucose intolerance with onset or first recognition during pregnancy 
    • It is diabetes that is first diagnosed in the 2nd or 3rd trimester of pregnancy that has not been a pre-existing type 1 or 2 diabetes  
  • Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios  
  • Prevalence of GDM appears to be high in South Asia and South East Asian women compared to African-American, Caucasian and Hispanic women; prevalence rates are 3-21.2% in women with GDM who were born in Asian countries  
    • Rates of fetal macrosomia are lower in South East Asian women than in American Caucasian women  
    • Asian women with GDM have a higher incidence of abnormal postpartum glucose tolerance tests and risk of developing type 2 DM in the future is higher than in Anglo-European women
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tee Hoi Poh, 26 Sep 2018
Stool-based colorectal cancer (CRC) screening should be the preferred method of CRC screening in Malaysia, according to Dato Dr Muhammad Radzi Abu Hassan, the Head of Gastroenterology Services in Ministry of Health, Malaysia, who presented the Malaysian experience on CRC screening at the Annual Scientific Meeting of the Society of Gastroenterology and Hepatology (GUT) 2018 held recently in Penang.
Jackey Suen, 26 Nov 2018

Linagliptin has no impact on cognitive decline when given on top of standard of care in patients with type 2 diabetes mellitus (T2DM), a CARMELINA substudy has shown.